

# Northumbria Research Link

Citation: Camargo Madeira Simoes, Davina and Vogiatzis, Ioannis (2018) Can muscle protein metabolism be specifically targeted by exercise training in COPD? *Journal of Thoracic Disease*, 10 (S12). ISSN 2072-1439

Published by: AME Publishing Company

URL: <http://doi.org/10.21037/jtd.2018.02.67> <<http://doi.org/10.21037/jtd.2018.02.67>>

This version was downloaded from Northumbria Research Link:  
<http://nrl.northumbria.ac.uk/id/eprint/33561/>

Northumbria University has developed Northumbria Research Link (NRL) to enable users to access the University's research output. Copyright © and moral rights for items on NRL are retained by the individual author(s) and/or other copyright owners. Single copies of full items can be reproduced, displayed or performed, and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided the authors, title and full bibliographic details are given, as well as a hyperlink and/or URL to the original metadata page. The content must not be changed in any way. Full items must not be sold commercially in any format or medium without formal permission of the copyright holder. The full policy is available online: <http://nrl.northumbria.ac.uk/policies.html>

This document may differ from the final, published version of the research and has been made available online in accordance with publisher policies. To read and/or cite from the published version of the research, please visit the publisher's website (a subscription may be required.)



23 **Abstract**

24 Patients with stable chronic obstructive pulmonary disease (COPD) frequently exhibit  
25 unintentional accentuated peripheral muscle loss and dysfunction. Skeletal muscle mass in  
26 these patients is a strong independent predictor of morbidity and mortality. Factors including  
27 protein anabolism/catabolism imbalance, hypoxia, physical inactivity, inflammation, and  
28 oxidative stress are involved in the initiation and progression of muscle wasting in these  
29 patients.

30 Exercise training remains the most powerful intervention for reversing, in part, muscle  
31 wasting in COPD. Independently of the status of systemic or local muscle inflammation,  
32 rehabilitative exercise training induces up-regulation of key factors governing skeletal muscle  
33 hypertrophy and regeneration. However, COPD patients presenting similar degrees of lung  
34 dysfunction do not respond alike to a given rehabilitative exercise stimulus. In addition, a  
35 proportion of patients experience limited clinical outcomes, even when exercise training has  
36 been adequately performed. Consistently, several reports provide evidence that the muscles  
37 of COPD patients present training-induced myogenic activity resistance as exercise training  
38 induces a limited number of differentially expressed genes, which are mostly associated with  
39 protein degradation.

40 This review summarises the nature of muscle adaptations induced by exercise training,  
41 promoted both by changes in the expression of contractile proteins and their function  
42 typically controlled by intracellular signalling and transcriptional responses. Rehabilitative  
43 exercise training in COPD patients induces skeletal muscle mechanosensitive signalling  
44 pathways for protein accretion and its regulation during muscle contraction. Exercise training  
45 also induces synthesis of myogenic proteins by which COPD skeletal muscle promotes  
46 hypertrophy leading to fusion of myogenic cells to the myofibre. Understanding of the  
47 biological mechanisms that regulate exercise training-induced muscle growth and  
48 regeneration is necessary for implementing therapeutic strategies specifically targeting  
49 myogenesis and hypertrophy in these patients.

50

51

52

53 Keywords: COPD, exercise, protein synthesis, anabolism, hypertrophy, myogenesis, muscle  
54 wasting

55

56 ***Introduction***

57 COPD is the fourth leading cause of death worldwide and is projected to be the third most  
58 common cause of death by 2020 (1). Cigarette smoke constitutes the major preventable risk  
59 factor, resulting in a progressive proteolytic, inflammatory and vasoactive response that leads  
60 to emphysema, small airway obstruction and pulmonary hypertension. The oxidative stress  
61 imposed by cigarette smoking together with systemic inflammation and hypoxia are  
62 important contributors to pathogenesis of skeletal muscle wasting and dysfunction and have  
63 been previously extensively reviewed (2-4). Skeletal muscle wasting is an important systemic  
64 effect of the disease and a strong independent predictor of mortality (5-7). This unintentional  
65 accentuated skeletal muscle wasting is frequently associated with altered muscle structure  
66 (fiber size, fiber type distribution, capillary density and metabolic capacity) and dysfunction  
67 (decreased strength and endurance). While the magnitude of the alterations varies  
68 substantially across individuals, some degree of muscle wasting affects all individuals during  
69 ageing. Age-related defects in protein metabolism have been proposed to be causally  
70 involved in this muscle loss (8). These changes are attributed to both inactivity- and age-  
71 related alterations in protein synthesis and degradation, indicating complex  
72 pathophysiological phenomena involving both structural changes to the muscle fibres, as well  
73 as the enzymatic machinery that controls metabolism. Independently of the factors promoting  
74 muscle wasting in COPD, regular physical exercise remains the most potent available  
75 treatment option for reversing, in part, locomotor muscle wasting and dysfunction in COPD  
76 (9). Indisputably, exercise training promotes a range of beneficial adaptations in the skeletal  
77 muscle including increased capillarization, fibre type plasticity, hypertrophy and function.  
78 However, exercise training induced muscle benefits are certainly much smaller in COPD  
79 patients compared to age matched controls. In addition, not all COPD patients respond  
80 adequately to exercise stimulus, even when exercise training is properly performed (10, 11).  
81 An improved understanding of molecular mechanisms of exercise induced adaptations in  
82 COPD and healthy individuals will be valuable to inform future directions to address the  
83 issues on resistance to exercise-induced adaptations in COPD.

84

85 ***Effect of prescribed exercise training to skeletal muscle adaptation in COPD***

86

87 Exercise training is a mechanical stimulus that consists of repeated, episodic bouts of muscle  
88 contraction promoting functional adaptation and remodelling not only to the skeletal muscle,

89 but also to various systems in our body (12, 13). Exercise promotes a range of adaptations  
90 that is beyond the musculoskeletal system promoting general health(14). Briefly, in parallel  
91 with neural signals to the skeletal muscle contraction, powerful neural feed-forward signals to  
92 the respiratory, cardiovascular, metabolic and hormonal systems are produced. In response to  
93 exercise training, COPD patients demonstrate reduction in dyspnea sensations, improvements  
94 in exercise capacity and quality of life (9).

95

96 Skeletal muscle adaptations are dependent on the intensity and duration of the exercise  
97 training performed (15). High intensity exercise training ( $W_{peak} \geq 80\%$ ) is generally  
98 described to promote improvement in exercise capacity. However, COPD patients with  
99 limited ventilatory capacity are usually unable to sustain high intensities for sufficiently long  
100 periods. Taking into consideration COPD patients exercise capacity, a number of studies have  
101 been performed employing a varied combination of exercise modalities/training, program  
102 duration and intensity. Usually, the duration of an exercise training programme is set from 8  
103 to 12 weeks and as frequent as 3 times per week. Combination of high intensity aerobic and  
104 resistance exercise is described to promote quantifiable muscle hypertrophy in COPD (16, 10,  
105 17, 11). Conversely, exercise training of lower intensity ( $W_{peak} \leq 60\%$ ) was found unable to  
106 promote quantifiable changes in muscle hypertrophy and fibre type distribution (18, 19).  
107 Therefore, programmes incorporating high intensity exercise training are more likely to  
108 induce quantifiable skeletal muscle adaptations.

109

110 Different modes of exercise such as endurance- and resistance-based are known to stimulate  
111 variable but specific skeletal muscle adaptations, leading to muscle endurance and strength  
112 respectively (15). Aerobic/endurance exercise training enhances mitochondrial protein  
113 content and oxidative capacity of trained myofibers, improving insulin sensitivity and skeletal  
114 muscle metabolic function (20). Whereas, resistance training increases myosin-heavy-chain  
115 gene transcripts and synthesis rate of muscle proteins promoting strength (15). When  
116 comparing different modalities of exercise prescribed to healthy sedentary people, Robinson  
117 et al (21) observed that high intensity interval training (HIIT) enhanced more  
118 comprehensively changes such as aerobic capacity, mitochondria respiration and lean body  
119 mass (21). HIIT training simultaneously promoted endurance- and resistance-based training  
120 skeletal muscle adaptations, that promoted changes in transcription and translation regulation  
121 of muscle growth and mitochondrial pathways (21). HIIT reversed age-related proteome,  
122 particularly of mitochondrial proteins. But both resistance training and HIIT increase proteins

123 involved in translational machinery. HIIT exercise involves 30s repeated short bouts of  
124 activity at near maximal intensity ( $W_{peak} \geq 80\%$ ) interspersed with 30s rest periods, which  
125 despite its high intensity, has been successfully applied to COPD patients (10, 17, 22, 11). A  
126 representation of basic skeletal muscle adaptation promoted by aerobic/endurance, resistance  
127 and HIIT is depicted in Figure 1, originally adopted by Robinson *et al.* (21).

128 Therefore, adaptations seen in COPD skeletal muscle take place in accordance with specific  
129 exercise training stimuli, thereby partially explaining the large variability in muscle  
130 adaptations seen among studies. The effect of exercise modalities in promoting COPD  
131 skeletal muscle adaptations at structural and protein metabolism levels have been recently  
132 presented in a systemic review (18).

133  
134 Histologically, the skeletal muscle appears uniform, but is composed by a range of  
135 heterogeneous myofibres regarding size, metabolism and contractile function. When  
136 comparing myosin-heavy-chain isoform expression, myofibres are classified into type I, type  
137 IIa, type IIc/x, and type IIb fibres (23). Type I and IIa fibers exhibit high oxidative potential  
138 and IIx and IIb are primarily glycolytic. Whether endurance- or resistance-based exercise  
139 training can induce myofibre plasticity is still debatable. Certainly, COPD patients present a  
140 shift in fibre type displaying fewer type I (oxidative) fibres and greater proportion of type II  
141 (glycolytic) fibres in quadriceps muscles (24). This shifting towards glycolytic fibres is  
142 associated with increased mortality (7). Exercise training prescribed to COPD patient can  
143 only partially reverse this fiber type shifting. Proportion of fiber type I and IIa were increased  
144 mainly after HIIT and high intensive aerobic exercise (18, 25) as endurance training confers  
145 an increased oxidative profile to trained myofibers (23). Hypertrophy of fibre type I and IIa  
146 was more widespread among different modalities of exercise training, (18), Whereas,  
147 capillary to fiber ratio adaptations were though observed across various intensities and  
148 modalities of exercise training (18).

149

### 150 ***Contribution of inactivity to COPD muscle wasting***

151

152 Inactivity appears to be an important mechanism in the process of muscle loss in COPD,  
153 given that muscles that are active, such as the diaphragm and the adductor pollicis, do not  
154 exhibit atrophy in contrast to inactive muscles, such as the quadriceps (26). In experiments  
155 comparing different muscle groups in COPD patients, the characteristics exhibited by the

156 deltoid and the diaphragm were different compared to the quadriceps (27). Importantly, the  
157 muscles of respiration in COPD exhibit a contrary shift in fiber typing compared to the  
158 locomotor muscles, manifested by increased type I fiber distribution (28, 29). Various  
159 conditions of reduction in neuromuscular activity promoted by inactivity are known to  
160 decrease myonuclear number in atrophying muscle and impact on fibre typing. As reviewed  
161 elsewhere (30), detraining experiments in healthy individuals have shown to induce  
162 locomotor muscle adaptations that lead to increased number of muscle fibre type Iix  
163 phenotype, and attenuation of mitochondrial biogenesis (PPARs and PGC-1 $\alpha$ ) as observed in  
164 COPD patients. As described above, reassuming activity by exercise training can partially  
165 promote changes in fibre type distribution (18). However, inactivity alone does not seem to  
166 fully explain the phenomenon of muscle fibre type shifting in COPD.

167

### 168 *Mechanical stress and mitogen-activated protein kinase signalling*

169

170 The ability of skeletal muscles to respond to physical exercise by executing the appropriate  
171 metabolic and transcriptional response is dependent upon the cellular signal transduction  
172 through phosphorylation cascades. Multiple kinases, including AMPK, Akt and the mitogen-  
173 activated protein kinases (MAPKs) are involved in the regulation of DNA transcription  
174 through the phosphorylation of nuclear transcription factors. This either enhances or inhibits  
175 the ability of transcription factors to bind DNA, affecting target gene transcription (31, 32).  
176 Three main MAPK subfamilies are activated by acute exercise in human skeletal muscle: (1)  
177 the extracellular-regulated kinase (ERK1/2), (2) the c-jun N-terminal kinase (JNK), and (3)  
178 the p38 MAPK. Activation of MAPKs regulates the transcriptional events by phosphorylation  
179 of diverse substrates localised in the cytoplasm or nucleus, including transcription factors,  
180 inducing differentiation, hypertrophy, inflammation, and gene expression (33).

181

182 The MAPK p38 is a stress-activated kinase that is transiently activated in response to a  
183 strenuous range of stimuli such as physical inactivity and increased intensity of exercise  
184 training (34, 35). Activation of p38 in skeletal muscle myoblasts is related to loss a in cell  
185 autonomous self-renewal capacity (36). MAPK p38 activation is also observed during  
186 skeletal muscle immobilisation in a rat hind limb model of acute muscle wasting (37, 34).  
187 COPD are generally more inactive compared to their age-matched healthy counterparts (38).

188 Accordingly, ratios of phosphorylated to total level of p38 MAPK and ERK 1/2 were  
189 significantly elevated in patients with COPD compared to controls (39). Whereas, another  
190 study have shown no differences in the ratio of phospho-p38 MAPK to total level of p38  
191 MAPK protein between COPD patients and healthy age-matched donors. Although patients  
192 with COPD present muscle wasting, discrepancies among studies would be expected as it is  
193 uncertain whether patients are actively losing muscle mass at the time of experimentation.

194

195 *Major signaling pathways involved in the control of exercise training induced skeletal*  
196 *muscle adaptations*

197

198 Endurance- and resistance-based modalities of exercise are controlled by two major signaling  
199 pathways regulating mitochondria biogenesis and hypertrophy respectively, as depicted in  
200 Figure 2.

201

202 The regulation of mitochondrial biogenesis by endurance-based exercise converge from  
203 activation of the cascades AMPK and p38 upregulating PGC-1 $\alpha$ . When compared to healthy  
204 controls, mitochondria density is lower in quadriceps muscle of COPD patients, presenting  
205 lower expression of peroxisome proliferator-activated receptors (PPARs), PPAR- $\gamma$  co-  
206 activator 1 $\alpha$  (PGC-1 $\alpha$ ) and mitochondrial transcription factor (TFAM) in cachectic COPD  
207 (40). In patients with COPD, exercise enhances the decrease in mitochondria DNA content of  
208 skeletal muscle and the expression of PGC-1 $\alpha$  mRNA seen in healthy subjects, probably due  
209 to oxidative stress (41).

210

211 In contrast, resistance training is described to stimulate the signaling pathways responsible  
212 for muscle hypertrophy (12, 13). The activation of mTOR and IGF-I appears to be important  
213 in this process. To restore muscle mass via regular exercise training, protein synthesis should  
214 exceed protein breakdown over an extended period. Hypertrophy of skeletal muscle as result  
215 of resistance exercise training is strongly associated with the degree of mTOR activation,  
216 ribosomal protein S6K (p70<sup>S6K</sup>) phosphorylation and downstream targets (42). Contraction-  
217 induced p70<sup>S6K</sup> activation is dependent on mTOR activation, which increases protein  
218 translation and inhibits protein degradation via inhibition of both ubiquitin proteasome (43,  
219 32, 44) and autophagy-lysosome pathways (45, 46). mTOR activation is critical to load-

220 induced muscle growth, as demonstrated by the attenuation of hypertrophy responses and  
221 protein synthesis by the mTOR inhibitor, rapamycin (43).

222

223 We and others have described that Akt/mTOR pathway is downregulated in skeletal muscle  
224 of patients with COPD compared to healthy subjects (10). HIIT promotes the activation of  
225 the Akt/mTOR pathway in skeletal muscle only in COPD patients with preserved muscle  
226 mass compared to aged matched controls. Some studies suggest that hypoxemia  
227 characteristically observed in more severe cachectic COPD patients, is associated with  
228 resistance of skeletal muscle activation of the Akt/mTOR pathway (16). Exercise training in  
229 hypoxemic patients with COPD was not capable to promote muscle fibre hypertrophy and  
230 activation of the Akt/mTOR pathway as compared to normoxemic COPD patients (16). Both  
231 *in vitro* C2C12 myotubes cultured in normoxic and hypoxic conditions and mice models of  
232 hypoxia suggest that the response of the Akt/mTOR pathway to exercise could be  
233 compromised in hypoxemic patients (16, 47). Therefore, impairment of skeletal muscle  
234 hypertrophy commonly linked to the severity of the disease is associated with the magnitude  
235 of muscle wasting, the degree of hypoxia, or both. Interestingly, induced expression of the  
236 adaptive response of hypoxia HIF-1 responsive RTP801 (DDIT4) is observed only in trained  
237 COPD and not in healthy subjects (48).

238

239 mTOR regulates the mechanisms of protein synthesis at several levels (e.g. translation  
240 capacity, translation efficiency) through increases of translation of specific mRNAs, which  
241 culminates in skeletal muscle fibre enlargement. mTOR exists as part of two multi-protein  
242 complexes: i) mTORC1, which contains raptor and confers rapamycin sensitivity, is required  
243 for signalling to p70<sup>S6K</sup> and 4E-BP1, whereas ii) mTORC2, which contains rictor and is  
244 rapamycin insensitive, is required for signalling to Akt-FOXO (49). The effect of mTOR  
245 activity on downstream regulators of protein synthesis is principally achieved through a  
246 contraction-induced regulation of mTORC1 (50).

247

248 Early work on adaptive hypertrophy has focused on the (transient) post exercise rise in blood-  
249 borne anabolic hormones, such as growth hormone and insulin-like growth factor-I (IGF-I),  
250 and the consequent activation of the muscle protein synthesis of a signalling cascade  
251 (phosphatidylinositol 3-kinase (PI3K)-Akt-mTOR) by IGF-I interaction with insulin and  
252 IGF receptors (51). Recently, the muscle growth paradigm has shifted focus to IGF-I-  
253 independent mechanisms of mTOR activation and adaptive hypertrophy through mechano-

254 sensory regulation (50). Nutrient-dependent regulation of muscle growth is achieved through  
255 insulin- and Akt-dependent activation of the mTOR pathways. These pathways operate  
256 synergistically causing muscle growth and can be augmented by appropriate nutritional  
257 intake such as post exercise carbohydrate and amino acid ingestion or increased dietary  
258 protein (52). Therefore, IGF-I is involved not only in hypertrophy but also in promoting  
259 myogenesis and muscle regeneration.

260

261 ***Regulation of skeletal muscle protein synthesis promoting myogenesis and muscle***  
262 ***regeneration***

263

264 Skeletal muscle hypertrophy is achieved by both positive protein balance and fusion of  
265 satellite cells to myofibres (Figure 1). It is a process that involves (1) accretion of protein in  
266 various cellular compartments via mechanosensitive signalling pathways that drive  
267 translation, and (2) the activation and recruitment of resident muscle stem cell (satellite cells)  
268 that differentiate to fusion-competent myoblasts (53, 54). Regulation of protein translation  
269 and synthesis promotes accretion, whereas activation and incorporation of satellite cells  
270 facilitates the addition of myofibrils to the muscle.

271

272 Myogenesis and muscle regeneration depend on critical steps for activation of quiescent  
273 satellite cell, proliferation, migration, differentiation, fusion and maturation. Fusion of a  
274 satellite cell to an existent myofibre results in an increase in the number of myonuclei, and  
275 thus the available total amount of genetic machinery for protein production (54). The average  
276 number of myonuclei per muscle fibre of non-cachectic COPD is twice as high compared to  
277 controls, indicating higher capacity of protein metabolism necessary for maintenance of  
278 muscle mass. Quiescent satellite cells are essential to replenishment of myonuclei pool. As  
279 satellite cells replicate throughout lifespan, telomeres are shortened. Telomere shortening is a  
280 marker of senescence. COPD patients, despite the observation that satellite cells numbers are  
281 unaltered in the limb muscle compared to controls, satellite cells present shorter telomeres. A  
282 fact suggesting exhausted muscle regenerative capacity, compromising the maintenance of  
283 muscle mass (55).

284

285 Satellite cells myogenic regulatory factors (MRF) and myostatin play important roles in  
286 myogenesis and muscle regeneration. mRNA and protein expression of the myogenic  
287 differentiation factor D (MyoD), involved in the proliferation process, has been shown to

288 increase in the skeletal muscle of non-cachectic COPD patients after HIIT, but no changes  
289 were observed in cachectic COPD patients after HIIT (10). MyoD protein expression was  
290 also increased after resistance training with or without nutritional supplementation in patients  
291 and healthy controls (56). mRNA expression of MRF myogenin, involved in the  
292 differentiation process, was not different between a resistance training group and a control  
293 group, while addition of testosterone supplementation to resistance training increased  
294 myogenin mRNA expression compared to the control group (57). mRNA and protein  
295 expression of the myogenic inhibiting factor myostatin, showed no significant change after  
296 resistance exercise training neither in patients nor in healthy controls, or after combined  
297 aerobic and resistance training (56, 16). After HIIT however, non-cachectic COPD patients  
298 showed a significant decrease in mRNA and protein expression of myostatin, while in  
299 cachectic COPD patients HIIT did not significantly alter mRNA or protein myostatin  
300 expression (10). In addition, mRNA expression of a negative regulator of cell proliferation  
301 Kruppel-like factor 10 (KLF11) was increased after aerobic training in patients, but not in  
302 healthy controls (48).

303

304 The IGF-I system plays an important role in the regulation of muscle cell growth, muscle cell  
305 proliferation and muscle cell survival (58, 59). After HIIT, mRNA expression of both IGF-I  
306 and the mechano-growth factor (MGF), an isoform of IGF-I, significantly increases. Both  
307 cachectic and non-cachectic COPD patients have shown enhanced MGF mRNA expression  
308 post-training (10). However, no significant increase in protein expression of IGF-I and MGF  
309 expression was observed in cachectic COPD patients in comparison to non-cachectic. Other  
310 exercise protocols such as combined aerobic and resistance training were not capable to  
311 increase the expression of the IGF-I variants (16). However, testosterone supplementation  
312 was found to increase the levels of IGF-I and MGF protein expression in COPD patients after  
313 resistance training (57).

314

### 315 ***Exercise induced changes in gene expression***

316 Comparing gene transcription among different modalities of exercise in healthy individuals,  
317 Robinson et al (21) found that HIIT promotes a stronger increase in gene transcripts than  
318 other modalities of exercise tested, particularly in older adults.

319 Skeletal muscle gene expression from COPD after high intensity aerobic exercise training  
320 compared to age-matched controls were analysed using Genechip Array (48). High aerobic  
321 exercise training induced up-regulation of quantitatively significantly fewer genes in the  
322 skeletal muscle of COPD (107 were upregulated and 124 were downregulated) compared  
323 with healthy controls (258 were upregulated and 315 were downregulated). Qualitatively,  
324 genes associated with protein degradation, such as oxidative stress, ubiquitin proteasome, and  
325 COX pathways were distinctly induced only in patients with COPD, potentially reflecting the  
326 specific molecular response of the muscle to exercise in COPD, thereby suggesting additional  
327 operating mechanisms for exercise limitation in these patients. Whether exercise training can  
328 sufficiently enhance muscle hypertrophy to outstrip muscle wasting in COPD patients with  
329 substantial muscle loss, remains an unresolved issue.

330

### 331 ***Regulation of skeletal muscle protein breakdown***

332

333 Muscle tissue homeostasis is maintained by a tight and complex balance between protein  
334 synthesis and degradation. Protein metabolism turnover is a dynamic process balancing  
335 protein synthesis and breakdown. Muscle wasting due to an increase in protein breakdown is  
336 a feature shared among many acute and chronic disease entities as well as healthy ageing.

337

338 Muscle wasting has primarily been attributed to increased protein degradation. Protein  
339 degradation in COPD patients peripheral muscles takes place through four proteolytic  
340 systems, including the ubiquitin-proteasome (UP) pathway, the calpain pathway, the caspase  
341 pathway, and the autophagy-lysosome (AL) pathway as reviewed elsewhere (60).

342

343 Exercise has been found to stimulate mitogen activated protein kinases MAPK-9 and MAPK  
344 activated protein kinase 3 (MAPKAPK-3) in COPD compared to healthy controls (48). The  
345 MAPK pathway, in turn activates forkhead transcription factors, involved in muscle protein  
346 degradation. When inflammatory response to exercise is limited, the muscle recovers in a  
347 timely manner; however, persistent systemic inflammation described in COPD, may be  
348 associated with muscle wasting and adversely impact on muscle protein metabolism (61).  
349 Numerous pathological indicators in COPD, namely systemic inflammation, hypoxia and  
350 oxidative stress most likely trigger catabolic processes in skeletal muscle, that are mediated  
351 by transcriptional regulators including nuclear factor kappa-light-chain-enhancer of activated  
352 B cells (NF-kB) and forkhead box O transcription factors (FOXOs). The activity of NF-kB is

353 increased in COPD compared with healthy age-matched individuals (18, 62, 10, 22) and in  
354 particular in patients with muscle wasting compared to those without muscle wasting (63,  
355 10). FOXO mRNA and protein expression is increased in patients with COPD (64-67, 62).  
356 The expression of FOXO-1 may be associated with physical inactivity as protein expression  
357 is increased in lower limbs compared to respiratory muscles in COPD patients, but not in  
358 healthy controls (68). Increased catabolic signaling through FOXO and NF- $\kappa$ B activation  
359 may induce gene expression of key factors in both ubiquitin proteasome system (UPS) (69,  
360 32) and the autophagy lysosome pathways (45).

361

### 362 *Concluding remarks*

363 Exercise training promotes a range of beneficial adaptations in the skeletal muscle including  
364 increased capillarization, fibre type plasticity, hypertrophy and function. All these adaptations  
365 are a result of exercise stimuli that challenges muscle homeostasis by activating networks of  
366 signalling molecules. Activation of kinases and pre-transcriptional regulation occurs rapidly  
367 during exercise and recovery, whereas protein transcription is subsequently regulated.  
368 Intensity, duration, and mode of the exercise stimuli collectively contribute to the relative  
369 activation and the magnitude of activated pathways and downstream targets (12, 13). All  
370 these parameters have to be considered when designing exercise studies, so results are  
371 comparable and can advance knowledge in the area. Future studies on the molecular  
372 mechanisms of exercise induced satellite cell myogenic capacity in COPD patients are  
373 fundamental for designing pharmacological and exercise training interventions aiming to  
374 address resistance to exercise-induced adaptations.

375

376 *Acknowledgment:* DCMS is supported by University of Northumbria Multidisciplinary  
377 Research Theme (MDRT).

378

379

380 *Author contribution:* DCMS and IV wrote the paper, DCMS and IV approved the final  
381 version of the manuscript

382

383

384

385 **References**

386

- 387 1. Vogelmeier CF, Criner GJ, Martinez FJ, et al., Global Strategy for the Diagnosis,  
388 Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report:  
389 GOLD Executive Summary. *Arch Bronconeumol*, 2017;53:128-49.
- 390 2. Barnes PJ and Celli BR, Systemic manifestations and comorbidities of COPD. *Eur*  
391 *Respir J*, 2009;33:1165-85.
- 392 3. Barreiro E, Peinado VI, Galdiz JB, et al., Cigarette smoke-induced oxidative stress: A  
393 role in chronic obstructive pulmonary disease skeletal muscle dysfunction. *Am J*  
394 *Respir Crit Care Med*, 2010;182:477-88.
- 395 4. Kim HC, Mofarrahi M, and Hussain SN, Skeletal muscle dysfunction in patients with  
396 chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*, 2008;3:637-  
397 58.
- 398 5. Gea J, Agusti A, and Roca J, Pathophysiology of muscle dysfunction in COPD. *J*  
399 *Appl Physiol* (1985), 2013;114:1222-34.
- 400 6. Hopkinson NS, Tennant RC, Dayer MJ, et al., A prospective study of decline in fat  
401 free mass and skeletal muscle strength in chronic obstructive pulmonary disease.  
402 *Respir Res*, 2007;8:25.
- 403 7. Patel MS, Natanek SA, Stratakos G, et al., Vastus lateralis fiber shift is an  
404 independent predictor of mortality in chronic obstructive pulmonary disease. *Am J*  
405 *Respir Crit Care Med*, 2014;190:350-2.
- 406 8. Gouspillou G, Bourdel-Marchasson I, Rouland R, et al., Mitochondrial energetics is  
407 impaired in vivo in aged skeletal muscle. *Aging Cell*, 2014;13:39-48.
- 408 9. Spruit MA, Singh SJ, Garvey C, et al., An official American Thoracic  
409 Society/European Respiratory Society statement: key concepts and advances in  
410 pulmonary rehabilitation. *Am J Respir Crit Care Med*, 2013;188:e13-64.
- 411 10. Vogiatzis I, Simoes DCM, Stratakos G, et al., Effect of pulmonary rehabilitation on  
412 muscle remodelling in cachectic patients with COPD. *Eur Respir J*, 2010;36:301-10.
- 413 11. Vogiatzis I, Terzis G, Stratakos G, et al., Effect of pulmonary rehabilitation on  
414 peripheral muscle fiber remodeling in patients with COPD in GOLD stages II to IV.  
415 *Chest*, 2011;140:744-52.
- 416 12. Coffey VG and Hawley JA, The molecular bases of training adaptation. *Sports Med*,  
417 2007;37:737-63.
- 418 13. Fluck M and Hoppeler H, Molecular basis of skeletal muscle plasticity--from gene to  
419 form and function. *Rev Physiol Biochem Pharmacol*, 2003;146:159-216.
- 420 14. Cartee GD, Hepple RT, Bamman MM, et al., Exercise Promotes Healthy Aging of  
421 Skeletal Muscle. *Cell Metab*, 2016;23:1034-47.
- 422 15. Egan B and Zierath JR, Exercise metabolism and the molecular regulation of skeletal  
423 muscle adaptation. *Cell Metab*, 2013;17:162-84.
- 424 16. Costes F, Gosker H, Feasson L, et al., Impaired exercise training-induced muscle fiber  
425 hypertrophy and Akt/mTOR pathway activation in hypoxemic patients with COPD. *J*  
426 *Appl Physiol* (1985), 2015;118:1040-9.
- 427 17. Vogiatzis I, Stratakos G, Simoes DCM, et al., Effects of rehabilitative exercise on  
428 peripheral muscle TNF alpha, IL-6, IGF-I and MyoD expression in patients with  
429 COPD. *Thorax*, 2007;62:950-6.
- 430 18. De Brandt J, Spruit MA, Derave W, et al., Changes in structural and metabolic muscle  
431 characteristics following exercise-based interventions in patients with COPD: a  
432 systematic review. *Expert Rev Respir Med*, 2016;10:521-45.

- 433 19. Guzun R, Aguilaniu B, Wuyam B, et al., Effects of training at mild exercise  
434 intensities on quadriceps muscle energy metabolism in patients with chronic  
435 obstructive pulmonary disease. *Acta Physiol (Oxf)*, 2012;205:236-46.
- 436 20. Lanza IR, Short DK, Short KR, et al., Endurance exercise as a countermeasure for  
437 aging. *Diabetes*, 2008;57:2933-42.
- 438 21. Robinson MM, Dasari S, Konopka AR, et al., Enhanced Protein Translation Underlies  
439 Improved Metabolic and Physical Adaptations to Different Exercise Training Modes  
440 in Young and Old Humans. *Cell Metab*, 2017;25:581-92.
- 441 22. Vogiatzis I, Terzis G, Nanas S, et al., Skeletal muscle adaptations to interval training  
442 in patients with advanced COPD. *Chest*, 2005;128:3838-45.
- 443 23. Saltin B, Henriksson J, Nygaard E, et al., Fiber types and metabolic potentials of  
444 skeletal muscles in sedentary man and endurance runners. *Ann N Y Acad Sci*,  
445 1977;301:3-29.
- 446 24. Natanek SA, Gosker HR, Slot IG, et al., Heterogeneity of quadriceps muscle  
447 phenotype in chronic obstructive pulmonary disease (COPD); implications for  
448 stratified medicine? *Muscle Nerve*, 2013;48:488-97.
- 449 25. Gouzi F, Prefaut C, Abdellaoui A, et al., Blunted muscle angiogenic training-response  
450 in COPD patients versus sedentary controls. *Eur Respir J*, 2013;41:806-14.
- 451 26. Man WD, Soliman MG, Nikolettou D, et al., Non-volitional assessment of skeletal  
452 muscle strength in patients with chronic obstructive pulmonary disease. *Thorax*,  
453 2003;58:665-9.
- 454 27. Gea JG, Pasto M, Carmona MA, et al., Metabolic characteristics of the deltoid muscle  
455 in patients with chronic obstructive pulmonary disease. *Eur Respir J*, 2001;17:939-45.
- 456 28. Levine S, Gregory C, Nguyen T, et al., Bioenergetic adaptation of individual human  
457 diaphragmatic myofibers to severe COPD. *J Appl Physiol (1985)*, 2002;92:1205-13.
- 458 29. Levine S, Kaiser L, Leferovich J, et al., Cellular adaptations in the diaphragm in  
459 chronic obstructive pulmonary disease. *N Engl J Med*, 1997;337:1799-806.
- 460 30. Bogdanis GC, Effects of physical activity and inactivity on muscle fatigue. *Front*  
461 *Physiol*, 2012;3:142.
- 462 31. Bergeron R, Ren JM, Cadman KS, et al., Chronic activation of AMP kinase results in  
463 NRF-1 activation and mitochondrial biogenesis. *Am J Physiol Endocrinol Metab*,  
464 2001;281:E1340-6.
- 465 32. Sandri M, Sandri C, Gilbert A, et al., Foxo transcription factors induce the atrophy-  
466 related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. *Cell*,  
467 2004;117:399-412.
- 468 33. Long YC, Widegren U, and Zierath JR, Exercise-induced mitogen-activated protein  
469 kinase signalling in skeletal muscle. *Proc Nutr Soc*, 2004;63:227-32.
- 470 34. Choi I, Lee K, Kim M, et al., Differential activation of stress-responsive signalling  
471 proteins associated with altered loading in a rat skeletal muscle. *J Cell Biochem*,  
472 2005;96:1231-43.
- 473 35. Yu M, Stepto NK, Chibalin AV, et al., Metabolic and mitogenic signal transduction in  
474 human skeletal muscle after intense cycling exercise. *J Physiol*, 2003;546:327-35.
- 475 36. Bernet JD, Doles JD, Hall JK, et al., p38 MAPK signaling underlies a cell-  
476 autonomous loss of stem cell self-renewal in skeletal muscle of aged mice. *Nat Med*,  
477 2014;20:265-71.
- 478 37. Childs SG, Muscle wasting. *Orthop Nurs*, 2003;22:251-7; quiz 8-9.
- 479 38. Pitta F, Troosters T, Spruit MA, et al., Characteristics of physical activities in daily  
480 life in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*,  
481 2005;171:972-7.

- 482 39. Lemire BB, Debigare R, Dube A, et al., MAPK signaling in the quadriceps of patients  
483 with chronic obstructive pulmonary disease. *J Appl Physiol* (1985), 2012;113:159-66.
- 484 40. Remels AH, Schrauwen P, Broekhuizen R, et al., Peroxisome proliferator-activated  
485 receptor expression is reduced in skeletal muscle in COPD. *Eur Respir J*,  
486 2007;30:245-52.
- 487 41. Puente-Maestu L, Lazaro A, Tejedor A, et al., Effects of exercise on mitochondrial  
488 DNA content in skeletal muscle of patients with COPD. *Thorax*, 2011;66:121-7.
- 489 42. Terzis G, Georgiadis G, Stratakos G, et al., Resistance exercise-induced increase in  
490 muscle mass correlates with p70S6 kinase phosphorylation in human subjects. *Eur J*  
491 *Appl Physiol*, 2008;102:145-52.
- 492 43. Bodine SC, Latres E, Baumhueter S, et al., Identification of ubiquitin ligases required  
493 for skeletal muscle atrophy. *Science*, 2001;294:1704-8.
- 494 44. Stitt TN, Drujan D, Clarke BA, et al., The IGF-1/PI3K/Akt pathway prevents  
495 expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO  
496 transcription factors. *Mol Cell*, 2004;14:395-403.
- 497 45. Mammucari C, Milan G, Romanello V, et al., FoxO3 controls autophagy in skeletal  
498 muscle in vivo. *Cell Metab*, 2007;6:458-71.
- 499 46. Zhao J, Brault JJ, Schild A, et al., FoxO3 coordinately activates protein degradation  
500 by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells.  
501 *Cell Metab*, 2007;6:472-83.
- 502 47. Favier FB, Costes F, Defour A, et al., Downregulation of Akt/mammalian target of  
503 rapamycin pathway in skeletal muscle is associated with increased REDD1 expression  
504 in response to chronic hypoxia. *Am J Physiol Regul Integr Comp Physiol*,  
505 2010;298:R1659-66.
- 506 48. Radom-Aizik S, Kaminski N, Hayek S, et al., Effects of exercise training on  
507 quadriceps muscle gene expression in chronic obstructive pulmonary disease. *J Appl*  
508 *Physiol* (1985), 2007;102:1976-84.
- 509 49. Sandri M, Signaling in muscle atrophy and hypertrophy. *Physiology* (Bethesda),  
510 2008;23:160-70.
- 511 50. Philp A, Hamilton DL, and Baar K, Signals mediating skeletal muscle remodeling by  
512 resistance exercise: PI3-kinase independent activation of mTORC1. *J Appl Physiol*  
513 (1985), 2011;110:561-8.
- 514 51. Adams GR and Mccue SA, Localized infusion of IGF-I results in skeletal muscle  
515 hypertrophy in rats. *J Appl Physiol* (1985), 1998;84:1716-22.
- 516 52. Rennie MJ, Wackerhage H, Spangenburg EE, et al., Control of the size of the human  
517 muscle mass. *Annu Rev Physiol*, 2004;66:799-828.
- 518 53. Adams GR and Bamman MM, Characterization and regulation of mechanical  
519 loading-induced compensatory muscle hypertrophy. *Compr Physiol*, 2012;2:2829-70.
- 520 54. Allen DL, Roy RR, and Edgerton VR, Myonuclear domains in muscle adaptation and  
521 disease. *Muscle Nerve*, 1999;22:1350-60.
- 522 55. Theriault ME, Pare ME, Maltais F, et al., Satellite cells senescence in limb muscle of  
523 severe patients with COPD. *PLoS One*, 2012;7:e39124.
- 524 56. Constantin D, Menon MK, Houchen-Wolloff L, et al., Skeletal muscle molecular  
525 responses to resistance training and dietary supplementation in COPD. *Thorax*,  
526 2013;68:625-33.
- 527 57. Lewis MI, Fournier M, Storer TW, et al., Skeletal muscle adaptations to testosterone  
528 and resistance training in men with COPD. *J Appl Physiol* (1985), 2007;103:1299-  
529 310.
- 530 58. Annunziata M, Granata R, and Ghigo E, The IGF system. *Acta Diabetol*, 2011;48:1-9.


- 531 59. Zanou N and Gailly P, Skeletal muscle hypertrophy and regeneration: interplay  
532 between the myogenic regulatory factors (MRFs) and insulin-like growth factors  
533 (IGFs) pathways. *Cell Mol Life Sci*, 2013;70:4117-30.
- 534 60. Hussain SN and Sandri M, Role of autophagy in COPD skeletal muscle dysfunction. *J*  
535 *Appl Physiol* (1985), 2013;114:1273-81.
- 536 61. Jagoe RT and Engelen MP, Muscle wasting and changes in muscle protein  
537 metabolism in chronic obstructive pulmonary disease. *Eur Respir J Suppl*,  
538 2003;46:52s-63s.
- 539 62. Puig-Vilanova E, Rodriguez DA, Lloreta J, et al., Oxidative stress, redox signaling  
540 pathways, and autophagy in cachectic muscles of male patients with advanced COPD  
541 and lung cancer. *Free Radic Biol Med*, 2015;79:91-108.
- 542 63. Fermoselle C, Rabinovich R, Ausin P, et al., Does oxidative stress modulate limb  
543 muscle atrophy in severe COPD patients? *Eur Respir J*, 2012;40:851-62.
- 544 64. Debigare R, Cote CH, and Maltais F, Ubiquitination and proteolysis in limb and  
545 respiratory muscles of patients with chronic obstructive pulmonary disease. *Proc Am*  
546 *Thorac Soc*, 2010;7:84-90.
- 547 65. Debigare R, Maltais F, Cote CH, et al., Profiling of mRNA expression in quadriceps  
548 of patients with COPD and muscle wasting. *COPD*, 2008;5:75-84.
- 549 66. Doucet M, Russell AP, Leger B, et al., Muscle atrophy and hypertrophy signaling in  
550 patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*,  
551 2007;176:261-9.
- 552 67. Guo Y, Gosker HR, Schols AM, et al., Autophagy in locomotor muscles of patients  
553 with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*,  
554 2013;188:1313-20.
- 555 68. Doucet M, Dube A, Joannisse DR, et al., Atrophy and hypertrophy signalling of the  
556 quadriceps and diaphragm in COPD. *Thorax*, 2010;65:963-70.
- 557 69. Gielen S, Sandri M, Kozarez I, et al., Exercise training attenuates MuRF-1 expression  
558 in the skeletal muscle of patients with chronic heart failure independent of age: the  
559 randomized Leipzig Exercise Intervention in Chronic Heart Failure and Aging  
560 catabolism study. *Circulation*, 2012;125:2716-27.

561

562

563

564



566

567


568 Figure 1: COPD skeletal muscle adaptations to various modalities of exercise training.  
 569 Exercise training is a powerful stimulus producing hypertrophy and regeneration of muscle  
 570 by increased protein metabolism and fusion of satellite cells to existent myofiber. Endurance-  
 571 and resistance-based exercise training programmes are characterised as stimuli capable for  
 572 increasing oxidative capacity and hypertrophy, respectively. Skeletal muscle adaptations  
 573 observed from combined endurance/resistance as well as high intensity interval training  
 574 reflect a wider range of stimuli. (The Figure was originally adopted by Robinson *et al.* (21)  
 575 and subsequently modified by authors).

576

577

578

579  
580  
581



582  
583  
584

585 Figure 2: Diagram of the major signalling pathways involved in the control of skeletal muscle  
586 hypertrophy and mitochondrial biogenesis. Voluntary exercise training activate  
587 kinases/phosphatases to mediate a specific exercise-induced signal. The cross talk among the  
588 numerous signalling pathways activated and the multiple site regulation produces a high  
589 sensitive and complex transduction network.